Cargando…
Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BMJ Publishing Group
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671976/ https://www.ncbi.nlm.nih.gov/pubmed/34907029 http://dx.doi.org/10.1136/jitc-2021-003644 |
| _version_ | 1784615262207606784 |
|---|---|
| author | Ortiz-Maldonado, Valentín Rives, Susana Español-Rego, Marta Alonso-Saladrigues, Anna Montoro, Mercedes Magnano, Laura Giné, Eva Pascal, Mariona Díaz-Beyá, Marina Castella, Maria Català, Albert Faura, Anna Rodríguez-Lobato, Luis Gerardo Oliver-Caldes, Aina Martínez-Roca, Alexandra Rovira, Montserrat González-Navarro, E Azucena Ortega, Juan Ramón Cid, Joan Lozano, Miquel Garcia-Rey, Enric Fernández, Sara Castro, Pedro Jordan, Iolanda Villamor, Neus Aymerich, Marta Torrebadell, Montserrat Deyà, Àngela Fernández de Larrea, Carlos Benitez-Ribas, Daniel Trias, Esteve Varea, Sara Calvo, Gonzalo Esteve, Jordi Urbano-Ispizua, Alvaro Juan, Manel Delgado, Julio |
| author_facet | Ortiz-Maldonado, Valentín Rives, Susana Español-Rego, Marta Alonso-Saladrigues, Anna Montoro, Mercedes Magnano, Laura Giné, Eva Pascal, Mariona Díaz-Beyá, Marina Castella, Maria Català, Albert Faura, Anna Rodríguez-Lobato, Luis Gerardo Oliver-Caldes, Aina Martínez-Roca, Alexandra Rovira, Montserrat González-Navarro, E Azucena Ortega, Juan Ramón Cid, Joan Lozano, Miquel Garcia-Rey, Enric Fernández, Sara Castro, Pedro Jordan, Iolanda Villamor, Neus Aymerich, Marta Torrebadell, Montserrat Deyà, Àngela Fernández de Larrea, Carlos Benitez-Ribas, Daniel Trias, Esteve Varea, Sara Calvo, Gonzalo Esteve, Jordi Urbano-Ispizua, Alvaro Juan, Manel Delgado, Julio |
| author_sort | Ortiz-Maldonado, Valentín |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8671976 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2021 |
| publisher | BMJ Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-86719762021-12-28 Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy Ortiz-Maldonado, Valentín Rives, Susana Español-Rego, Marta Alonso-Saladrigues, Anna Montoro, Mercedes Magnano, Laura Giné, Eva Pascal, Mariona Díaz-Beyá, Marina Castella, Maria Català, Albert Faura, Anna Rodríguez-Lobato, Luis Gerardo Oliver-Caldes, Aina Martínez-Roca, Alexandra Rovira, Montserrat González-Navarro, E Azucena Ortega, Juan Ramón Cid, Joan Lozano, Miquel Garcia-Rey, Enric Fernández, Sara Castro, Pedro Jordan, Iolanda Villamor, Neus Aymerich, Marta Torrebadell, Montserrat Deyà, Àngela Fernández de Larrea, Carlos Benitez-Ribas, Daniel Trias, Esteve Varea, Sara Calvo, Gonzalo Esteve, Jordi Urbano-Ispizua, Alvaro Juan, Manel Delgado, Julio J Immunother Cancer Letter BMJ Publishing Group 2021-12-14 /pmc/articles/PMC8671976/ /pubmed/34907029 http://dx.doi.org/10.1136/jitc-2021-003644 Text en © Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
| spellingShingle | Letter Ortiz-Maldonado, Valentín Rives, Susana Español-Rego, Marta Alonso-Saladrigues, Anna Montoro, Mercedes Magnano, Laura Giné, Eva Pascal, Mariona Díaz-Beyá, Marina Castella, Maria Català, Albert Faura, Anna Rodríguez-Lobato, Luis Gerardo Oliver-Caldes, Aina Martínez-Roca, Alexandra Rovira, Montserrat González-Navarro, E Azucena Ortega, Juan Ramón Cid, Joan Lozano, Miquel Garcia-Rey, Enric Fernández, Sara Castro, Pedro Jordan, Iolanda Villamor, Neus Aymerich, Marta Torrebadell, Montserrat Deyà, Àngela Fernández de Larrea, Carlos Benitez-Ribas, Daniel Trias, Esteve Varea, Sara Calvo, Gonzalo Esteve, Jordi Urbano-Ispizua, Alvaro Juan, Manel Delgado, Julio Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
| title | Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
| title_full | Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
| title_fullStr | Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
| title_full_unstemmed | Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
| title_short | Factors associated with the clinical outcome of patients with relapsed/refractory CD19(+) acute lymphoblastic leukemia treated with ARI-0001 CART19-cell therapy |
| title_sort | factors associated with the clinical outcome of patients with relapsed/refractory cd19(+) acute lymphoblastic leukemia treated with ari-0001 cart19-cell therapy |
| topic | Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8671976/ https://www.ncbi.nlm.nih.gov/pubmed/34907029 http://dx.doi.org/10.1136/jitc-2021-003644 |
| work_keys_str_mv | AT ortizmaldonadovalentin factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT rivessusana factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT espanolregomarta factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT alonsosaladriguesanna factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT montoromercedes factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT magnanolaura factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT gineeva factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT pascalmariona factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT diazbeyamarina factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT castellamaria factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT catalaalbert factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT fauraanna factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT rodriguezlobatoluisgerardo factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT olivercaldesaina factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT martinezrocaalexandra factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT roviramontserrat factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT gonzaleznavarroeazucena factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT ortegajuanramon factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT cidjoan factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT lozanomiquel factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT garciareyenric factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT fernandezsara factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT castropedro factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT jordaniolanda factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT villamorneus factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT aymerichmarta factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT torrebadellmontserrat factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT deyaangela factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT fernandezdelarreacarlos factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT benitezribasdaniel factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT triasesteve factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT vareasara factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT calvogonzalo factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT estevejordi factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT urbanoispizuaalvaro factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT juanmanel factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy AT delgadojulio factorsassociatedwiththeclinicaloutcomeofpatientswithrelapsedrefractorycd19acutelymphoblasticleukemiatreatedwithari0001cart19celltherapy |